Malathi Hari Selected Research

Neoplasms (Cancer)

6/2006	Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
2/2006	Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
5/2005	Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin.
10/2004	Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
4/2003	HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Malathi Hari Research Topics

Disease

5	Neoplasms (Cancer) 06/2006 - 04/2003
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2004
1	Breast Neoplasms (Breast Cancer) 10/2004
1	Carcinoma (Carcinomatosis) 04/2003

Drug/Important Bio-Agent (IBA)

4	Paclitaxel (Taxol)FDA LinkGeneric 06/2006 - 04/2003
4	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 02/2006 - 04/2003
3	HTI-286IBA 05/2005 - 04/2003
1	taxaneIBA 06/2006
1	MST 997IBA 06/2006
1	Docetaxel (Taxotere)FDA Link 06/2006
1	CL 347099IBA 02/2006
1	hemiasterlinIBA 05/2005
1	Proteins (Proteins, Gene)FDA Link 10/2004
1	multidrug resistance-associated protein 1IBA 10/2004
1	Vincristine (Oncovin)FDA LinkGeneric 04/2003